2026-04-17T12:59:50Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/131352025-10-23T14:29:36Zcom_2072_378071com_2072_378040col_2072_378097

00925njm 22002777a 4500 dc Roca-Grande, Josep author Muñoz-Almagro, Carmen author Puigsech Boixeda, Guillem author VIÑADO, BELEN author Mir-Cros, Alba author Lung, Mayli author Bellés, Alba author Càmara, Jordi author Martin, Andrea author Moreno-Mingorance, Albert author González-López, Juan José author Larrosa, María Nieves author 2025-05-26T10:07:44Z 2025-05-26T10:07:44Z 2025 Neisseria meningitidis; Antimicrobial susceptibility; Whole genome sequencing Neisseria meningitidis; Susceptibilidad antimicrobiana; Secuenciación del genoma completo Neisseria meningitidis; Susceptibilitat antimicrobiana; Seqüenciació del genoma complet Invasive meningococcal disease (IMD) is associated with significant global morbidity and mortality and is addressed by conjugated polysaccharide and subcapsular vaccines. In Spain, data on 4CMenB vaccine strain coverage and antimicrobial susceptibility are limited. This study aimed to describe the genomic epidemiology, predict 4CMenB vaccine strain coverage, and assess antimicrobial susceptibility of 323 Neisseria meningitidis isolates causing IMD, collected from 57 Clinical Microbiology Laboratories in Spain over 12 years (2011/12–2022/23). Whole genome sequencing was performed to identify serogroup, clonal complex (cc), and antimicrobial resistance determinants. Vaccine strain coverage for serogroup B (MenB) isolates was predicted using the genetic Meningococcal Antigen Typing System approach. The most prevalent serogroups were B (57.9%), W (21.4%), C (10.4%), and Y (8.4%). MenB predominated throughout most seasons, except during the 2019/20 season when serogroup W peaked. Post-COVID-19 pandemic, MenB remained the most frequent (70.2%). Thirteen cc were identified among MenB isolates, with cc213 being the most prevalent (40.1%). Only 28.9% of MenB isolates were predicted to be covered by 4CMenB, with cc213 showing an exceptionally low coverage rate (5.3%) due to antigenic variants poorly targeted by the vaccine. Notably, cc213 was responsible for twice the proportion of MenB cases in 4CMenB-vaccinated versus unvaccinated. All isolates were susceptible to third generation cephalosporins, and 13.5% showed penicillin resistance. This study highlights the alarming prevalence of cc213 among MenB IMD cases in Spain and the limited 4CMenB coverage against this cc. The disproportionate representation of cc213 in vaccinated individuals underscores its potential to compromise vaccine effectiveness. This work was supported by the “Instituto de Salud Carlos III” and cofinanced by the European Regional Development Fund (ERDF) grant number FIS PI21/00132, and by the “Centro de Investigación Biomédica en Red” (CIBER de Enfermedades Infecciosas) grant number CB21/13/00054. Genomes bacterians Medicaments antibacterians Meningococcèmia - Prevenció Vacunes antibacterianes ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Genetic Techniques::Sequence Analysis::Sequence Analysis, DNA::Whole Genome Sequencing CHEMICALS AND DRUGS::Complex Mixtures::Biological Products::Vaccines::Bacterial Vaccines::Meningococcal Vaccines DISEASES::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections::Neisseriaceae Infections::Meningococcal Infections Other subheadings::Other subheadings::Other subheadings::/prevention & control CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas genéticas::análisis de secuencias::análisis de secuencias de ADN::secuenciación del genoma completo COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::productos biológicos::vacunas::vacunas bacterianas::vacunas antimeningocócicas ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias gramnegativas::infecciones por Neisseriaceae::infecciones meningocócicas Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos Genomic characterization of invasive Neisseria meningitidis in Spain (2011/12–2022/23): expansion of clonal complex 213 and the potential threat to 4CMenB vaccine strain coverage